Despite the great potential of gene therapy to become a new treatment modality in future medicine, there are still many limitations to overcome before this gene approach can pass to the stage of human trial. The foremost obstacle is the development of a safe, efficient, and efficacious vector system for in vivo gene application. This study evaluated the efficacy of lipofection as a gene delivery vehicle into primary endothelial cells. Transfection efficiency of several lipid-based reagents (Effectene, Fugene 6, DOTAP) was examined at experimental temperatures of 37°C, 24°C, and 6°C. Human umbilical vein endothelial cells (HUVECs) were transfected with the enhanced green fluorescent protein (EGFP) using precise amounts of DNA (Effectene, 0.2 µg; Fugene 6, 0.5 µg; DOTAP, 2.5 µg) and lipids (Effectene, 10 µl; Fugene 6, 6 µl; DOTAP, 15 µl) optimized in our laboratory. Duration of incubation in the DNA/lipid transfection mixture varied for each lipid transfectant as follows: 5 h for both Fugene 6 and DOTAP and 3 h for Effectene. Efficiency of transfection was quantified by microscopic evaluation of EFGP expression in a minimum of 100 cells per group. Transfection efficiencies achieved with these lipofection agents were 34 ± 1.3% (mean ± SEM), 33 ± 1.4%, and 18 ± 1.5% for Effectene, Fugene 6, and DOTAP, respectively, at 37°C. Transfection results were lower at 24°C with mean efficiencies of 26 ± 2.4% for Effectene, 14 ± 2.9% for Fugene 6, and 15 ± 3.2% for DOTAP. Furthermore, mean efficiencies at 6°C were 6 ± 0.5%, 8 ± 1.5%, and 6 ± 0.0% for Effectene, Fugene 6, and DOTAP, respectively. Efficiency of transfection appeared to be temperature dependent (ANOVA; p < 0.0001). In spite of a significant decrease (37°C vs. 24°C: p < 0.0001; 37°C vs. 6°C: p < 0.0001; 24°C vs. 6°C: p < 0.0115) in transfection efficiency at low temperatures, the successful in vitro gene manipulation renders lipofection a potential gene delivery strategy for in vivo gene therapy. 573 574 YOUNG ET AL.
INTRODUCTION
of chronic diseases including cystic fibrosis, AIDS, cancer, diabetes, and vascular diseases (8, 15, 19, 39) . Several The basis of gene therapy is the introduction of a hundred human gene therapy clinical trials have been normal gene into somatic cells, which express the deapproved worldwide with over 100 protocols implesired gene product that may function either in: 1) cormented in the United States alone (3, 19, 36) . Unforturecting a cellular dysfunction, 2) imparting a new funcnately, gene therapy has never reached beyond the stage tion, or 3) inhibiting an unfavorable cellular process of human clinical trial (17) . One of several major obsta- (19, 36) . The rationale is to provide remedy at the most cles is the development of a safe, efficient, and efficafundamental level; that is, to effect a cure by intervening cious vector system for in vivo gene application (3). in the disease process via somatic gene manipulation This impediment remains at the forefront in the field of (17) . gene therapy (7). Gene therapy was originally developed for inherited Approximately 75% of human clinical trials have disorders (53). Since the initial reported success from adopted viral-mediated gene transfer technologies that the first human clinical trial in 1990 for adenosine deamare much more efficient than nonviral-mediated vector inase (ADA) deficiency, gene therapy has become the systems (19) . The majority of the protocols have emfocus of numerous treatment protocols (6, 17, 36, 42) . Apployed retrovirus as a method of gene delivery due to plication of gene therapy has been extended to treatment its stable long-term expression and high infection rates in proliferating cells (1, 31, 48) . Slowly replicating or of 37°C, 24°C, and 6°C. Confluent flasks of HUVECs of low passages (p ≤ 6) were plated onto six-well Trans-nondividing endothelial cells (ECs) of the vascular endothelium become problematic for this particular viral well plates for transfection studies. The plated cell density varied, ranging from 1.2 to 3 × 10 5 cells/well and vector (19, 43) . Efficiency of gene transfer has been as low as 0.5% to 1% (20, 54) . Nonetheless, successful in cultured for 1 to 3 days depending on their growth rate. When they reached approximately 80% to 90% conflu-vivo gene transfer to specific sites using retroviral and liposomal vectors has been documented (32) albeit at ence the plated HUVEC monolayer was transfected at experimental temperatures of 37°C, 24°C, and 6°C with extremely low efficiencies compared to adenovirus (18, 51) . Although liposome-mediated transfection is one of the three commercial lipid-based reagents: Fugene 6, DOTAP, and Effectene. Optimization of the pro-second to adenovirus (29) in efficiency, nonviral vectors are biologically safer for in vivo application (43) .
vided commercial protocols to achieve high levels of reporter gene expression for these lipid transfectants was To date, many studies have shown that transfection efficiency using lipid-based gene transfer technologies done at 37°C. These optimized transfection parameters (DNA/lipid ratios, DNA/lipid doses, duration in trans-is remarkably low in primary cells (9, 15, 40, 46) . We are interested in optimizing these nonviral vectors for poten-fection mixture) were maintained for transfections at 24°C and 6°C. In addition to a negative control, a 37°C tial ex vivo transfection of allografts prior to transplantation. We assessed the in vitro transfection of primary temperature control was also carried out in transfection experiments done at temperatures other than 37°C. human umbilical vein endothelial cells (HUVECs) utilizing three different commercial lipid-based reagents, Transfection mixtures containing reporter DNA and lipid reagent were prepared according to commercial Effectene (Qiagen, ON), Fugene 6 (Roche Molecular Biochemicals, IN), and DOTAP (Roche Molecular Bio-protocols. The HUVEC monolayer was washed twice with serum-free medium, Opti-MEM I (GIBCO), then chemicals), at experimental temperatures of 37°C, 24°C, and 6°C. Using the enhanced green fluorescent protein overlayed with 1 ml Opti-MEM I. Transfection mixtures were added dropwise while swirling the monolayer of (EGFP) as a reporter, the performance of each lipofection agent was evaluated based on percent transfection. cells. At the end of the incubation period the transfection mixture was removed, the monolayer washed twice with MATERIALS AND METHODS M199 growth medium (no antibiotic), and then cultured Human Umbilical Vein Endothelial Cell Isolation in the same medium in an incubator at 37°C and 5% and Culture CO 2 /balance humidified air for 3 days.
Primary endothelial cells (ECs) were isolated from
Reporter Gene and Transfection Efficiency human umbilical cord vein (HUVECs) as previously de-Efficiency of transfection was determined using the scribed (16) . Briefly, the cord was digested with Type enhanced green fluorescent protein (EGFP) as a reporter V collagenase (0.2 mg/ml, Sigma) for 10 min at 37°C driven by a pCMV promoter and cloned in a pEGFP-NI and then flushed thoroughly with phosphate-buffered vector (Clontech, CA). Transfected ECs expressed EGFP saline (PBS, pH 7.4) to remove ECs from the cords (16) . and fluoresced green under darkfield fluorescence mi-ECs were collected in a 50-ml conical tube and pelleted croscopy, whereas untransfected control cells had no at 1000 × g for 10 min. Isolated ECs were cultured in 3 fluorescence ( Fig. 1 ). Endothelial cells were detached ml of complete M199 medium (GIBCO) supplemented from the culture dish with 0.5× trypsin-EDTA, washed, with 20% fetal bovine serum, L-glutamine (1.4 mM), and resuspended in PBS. An aliquot of cell suspension and penicillin/streptomycin (200 U/ml, 200 mg/ml) at was spread on a glass slide for assessment of transfec-37°C and 5% CO 2 in 95% air. Endothelial cell growth tion efficiency based on expression of the green fluoressupplement (5 mg/ml, ECGS-Beckon Dickensen) was cent protein. Transfection efficiency was evaluated by also provided to the cell culture. Upon confluence in the counting the number of fluorescing ECs under darkfield uncoated 25-cm 2 flask (VWR) the cells were washed from the total number of cells present in the same field with 1× Hanks solution (GIBCO), removed with 0.5× viewed under light microscopy. A minimum of 100 cells trypsin/EDTA (GIBCO), and spun down at 1000 × g for were evaluated, in duplicate, from each experimental 10 min. After removal of the supernatant the cell pellet group. was resuspended in complete M199 growth medium and A negative control vector was prepared in our laboratransferred to a 75-cm 2 (VWR) gelatin-coated flask. tory using the same plasmid backbone as the pEGFP-NI Subsequent confluent flasks were subcultured at a 1:3 vector by removing the EGFP gene (719 bp) with the split ratio into 75-cm 2 gelatinized flasks. restriction enzymes, EcoRI and NotI. Incompatible ter-Primary Endothelial Cell Transfection Studies mini of the remaining vector fragment were filled by an end-filling reaction using the Klenow fragment of DNA The temperature dependence with lipid transfection was assessed by experiments carried out at temperatures polymerase I and ligated with T4 DNA ligase. Cloned DNA plasmids were then purified using an endotoxin-ing ECs occurred at 6°C with a mean expression level of 6 ± 0.6% (n = 6). At 24°C, the mean efficiency was free maxi-prep kit (Qiagen). Transfection with this empty vector was done under the same experimental 18 ± 2.1% (n = 17). Efficiency of transfection using lipofection appears to be adversely affected by the de-conditions as the test samples. Results of percent transfection were expressed as the mean ± SEM. Statistical creasing temperatures. significance between the three experimental groups at Comparison of Performance Among Individual different temperatures was evaluated by ANOVA fol-Lipid Reagents lowed by the Scheffé F test, and p < 0.05 was considered significant.
The performance of individual lipotransfectant was compared based on percent transfection (Fig. 6 ). Effec-RESULTS tene reagent is a unique nonliposomal formulation that Optimization of Lipofection is used with a DNA-condensing enhancer and optimized buffer to achieve high transfection efficiency in eukary-To avoid in vitro toxicity and achieve optimal transotic cells. Transfection of HUVECs with Effectene refection efficiency with lipofection, it is necessary to opsulted in 34 ± 1.3% (n = 13) mean efficiency at 37°C. timize the transfection protocol for each lipid-based re-Lowering the temperature to 24°C resulted in a decrease agent. Parameters evaluated included the DNA and lipid in mean efficiency to 24 ± 3.1% (n = 7). Further decline dose, DNA/lipid ratio, and duration of incubation in the in transfection efficiency was noted at 6°C at which transfection mixture. The amounts of plasmid DNA and gene expression was 6 ± 0.5% (n = 2). Untransfected lipid reagent used and found to be optimal for each procontrol HUVECs had no fluorescence. tocol were as follows: 0.5 µg DNA/6 µl of Fugene 6, Fugene 6 is another nonliposomal reagent comprised 2.5 µg DNA/15 µl DOTAP, and 0.2 µg DNA/10 µl of of a blend of lipids and other compounds combined in Effectene. Recommended incubation time in the trans-80% ethanol. Comparable transfection efficiency to Effection mixture also varied among the lipid reagents: 5 fectene was achieved with Fugene 6 at 37°C, which was h for both Fugene 6 and DOTAP and 3 h for Effectene 30 ± 2.5% (n = 7). Similarly, as the temperature declined ( Fig. 1 ). For these incubation periods minimal toxicity mean transfection efficiency also decreased, but the was observed. Fugene 6 appeared the least toxic by the magnitude of decrease was greater for Fugene 6 than low degree of cell detachment observed after incubation Effectene at 24°C. Mean transfection efficiency was in the DNA/lipid mixture.
14 ± 2.9% (n = 6) and at 6°C it was 8 ± 1.5% (n = 2).
Temperature-Dependent Effect on Lipid Transfection
Among the three commercial lipid-based reagents studied lowest transfection efficiency was obtained with Rate of lipid-based transfection was temperature dependent (ANOVA; p < 0.0001) ( Figs. 2-4) , and the DOTAP transfection. DOTAP is a cationic liposomal formulation and this difference may account for the combined mean efficiency from all three lipid reagents (Effectene, Fugene 6, DOTAP) decreased significantly lower transfection results. At 37°C, mean transfection efficiency was 18 ± 2.3% (n = 7), which was only half (37°C vs. 24°C, p < 0.0001; 37°C vs. 6°C, p < 0.0001; 24°C vs. 6°C, p < 0.0115) as the temperature decreased as efficient as both Effectene and Fugene 6. However, at 24°C, the magnitude of decline in percent transfection (Fig. 5 ). Highest mean efficiency was observed at 37°C with 29 ± 1.7% (n = 25, mean ± SEM) cells expressing was small, mean efficiency was 15 ± 3.2% (n = 5), and even lower at 6°C, with resultant mean efficiency of EGFP, whereas the lowest percentage of EGFP-express- 6 ± 0.0% (n = 2). Among the three lipid formulations, it time. Another disadvantage is the requirement to use autologous cells for gene modification to eliminate the risk appears that Effectene performs relatively better at the different temperatures assessed (Fig. 6 ). of alloimmunity following transplantation (32,43). These drawbacks can be overcome by in vivo gene ther-DISCUSSION apy where the exogenous gene can be directly transferred to any specific site (32) using various delivery Gene therapy has arisen from a well-supported theory in the early 1970s to having immense practical implica-strategies. Direct gene transfer in vivo, though it is a method of relative ease and has widespread applicabil-tions in clinical medicine today (14) . Although it is still a developing clinical strategy, the versatility of gene ity, is limited by the low efficiency of gene delivery (20, 36, 38) . therapy has opened up new doors to different treatment approaches for both genetic and acquired diseases. Two Located at the interface between the circulation and the surrounding tissues the vascular endothelium is a tre-forms of gene therapy, ex vivo and in vivo, have been utilized in human clinical trials with thrice the number mendously appealing site for gene therapeutics. Although the quiescent endothelium is an excellent target of successful protocols adopting an ex vivo approach (6). Ex vivo gene manipulation involves the removal, site for gene therapy (28, 40) , ECs are difficult to transfect because of their slow proliferative rate both in vivo modification in vitro, and reintroduction of the modified autologous cells back into the host to deliver a specific and in vitro (24) . Low efficiency of gene transfer has been demonstrated in primary ECs using replication-transgene product (53). Using this approach a specific cell type can be targeted for gene transfer (43) and the deficient recombinant viral vectors, which usually give high infection rates (20) . However, unlike adenovirus, level of transgene expression can be evaluated prior to reimplantation. Unfortunately, ex vivo gene manipula-retrovirus is effective in transducing only replicating cells (42). To increase in vitro transduction DEAE-tion is a multistep process involving long preparation dextran was added to the retroviral-infected cultures and (24, 29, 39) . Use of this viral vector resulted in no significant inflammation reported in these studies except for a efficiency reached 50-90% (20) . Seeding experiments showed high coverage of retroviral-transduced ECs on study completed by French et al. (13) . Periadventitial cellular infiltrate in adenoviral-infected arteries was denuded vessel walls after being sparsely implanted following ex vivo manipulation (5, 12, 28, 31, 52) . Retroviral found that might be responsible for the decline in transgene expression. Immunogenicity and systemic toxicity transduction of vascular cells in vivo is highly inefficient compared with in vitro manipulation (6,20), ren-associated with high titral administration are safety issues limiting the widespread use of adenovirus in human dering this vector less competent than adenovirus for in vivo gene transfer into quiescent cell types.
gene therapy (4,7,36). As with all other biological vectors, biosafety is a major limitation for human clinical Adenovirus is the predominant vector used almost entirely for in vivo human gene transfer trials (6). It trial (10). Insertional mutagenesis and reversion to replication-competent virus are huge limiting factors when transfects dividing and nondividing cells with high efficiency both in vivo and in vitro. In vitro transduction using retrovirus for ex vivo gene manipulation (14) . Finding a safer and more efficacious gene delivery pro-with adenovirus is 10-100-fold greater than nonviral vectors, ranging from 50% to 100% efficiency in previ-tocol now becomes the focus and ultimate goal of gene therapy studies before this gene approach can advance ous studies (9, 13, 15, 22, 24, 29, 35) . Adenovector is also a far more superior vector in vivo. Successful gene trans-beyond human trial. A safer alternative to viral gene transfer is lipofec-fer to the intact endothelium has been documented (18, 24, 29) . Transfection of porcine coronary arteries in vivo tion. Lipofection is neither immunogenic nor pathogenic (7). However, lipofection generally gives much lower with recombinant adenovirus reached 100 times greater efficiency than with Lipofectin (13) . Although transgene efficiency, especially in primary ECs (9,27,34,40). Transfection in primary cell types is more problematic be-expression is transient, it may last from weeks to months cause they contain abundant nucleases that degrade lipid complexes to the cell membrane, thereby avoiding the endo-lysosomal pathway by this direct transfer to foreign DNA upon endocytosis (6). There have been developments in pH-sensitive liposomes and improved the cytosol (49) . Gene therapy is being revitalized for treatment of human disease through these improvements formulations of cationic liposomes and other lipid transfectants that are better capable of evading DNA degrada-in gene transfer technologies. Unfortunately, primary cells of human origin have al-tion. These modifications have improved transfection efficiency (11,23,37,47) astronomically from less than 1% ways been more difficult to transfect with nonviralmediated vectors (27, 40, 46, 50) . Teifel et al. reported an up to 70% (22, 25, 34, 46) . Improvement in efficiency has been documented in studies with primary ECs of porcine in vitro efficiency of 0.68% for electroporation and 0.45% for DOTAP (46) . In contrast, transfection with and bovine origins that were transfected at 15.2% with Lipofectamine (29) and 60-70% with Fugene 6 (22) .
DOTAP was 18% in our study (Fig. 4 ). Transfection of an endothelial cell line, EA.hy 926, was also extremely The degree of procedural optimization, cell type, and lipid reagent selected are all crucial factors affecting the low (9,46) with a reported efficiency of less than 0.5% for EA.hy 926 with Lipofectamine (9). Although Sipehia outcome of transfection. Undoubtedly, Fugene 6 appears to be relatively efficient in delivering gene(s) into refrac-et al. achieved an efficiency of 22.6% with ApoE-lipofection, which is targeted to specifically HUVECs, this tory cell types as shown by several earlier studies (22, 26, 50) . New lipid formulas may facilitate the escape result was lower than what we achieved with lipofection alone using Effectene and Fugene 6 (40). We were also of the DNA/lipid complexes from enzymatic degradation by rupturing the endosomes to make their immedi-able to transfect HUVECs at low temperatures, albeit at low efficiency, yet the levels of gene expression ate release prior to endo-lysosomal fusion (49) . Alternatively, DNA uptake can be mediated by fusion of DNA/ achieved were higher than those obtained in some previ- ous studies (25, 27, 40, 46) . The decline in transfection ef-a low metabolic state. This observation was more pronounced at 6°C than at RT. Shorter incubation times ficiency as a result of lowering the temperature may be associated with a reduction in cellular metabolism af-were used in our study than what were used in previous studies (2, 22, 40, 46) . Ideally, the minimal exposure time fecting gene expression as opposed to transfection. In addition, the DNA/lipid complexes may be more stable to lipotransfectant needed to achieve optimal in vivo transfection is preferred to minimize the risks of sys-at colder temperature, thereby sequestering the DNA and preventing its release and translocation to the nu-temic toxicity and tissue pathology. In summary, lipofection is an efficient method of gene transfer to primary cleus for transcription (21) . At lower temperatures the ECs appeared retracted and shriveled up, consistent with HUVECs as demonstrated by our study (Figs. 2-4 ). We Figure 6 . Percent transfection was expressed as the mean ± SEM. Resulting efficiencies were 34 ± 1.3% (n = 13), 33 ± 1.4% (n = 5), and 18 ± 1.5% (n = 7) for Effectene, Fugene 6, and DO-TAP, respectively, at 37°C. Mean efficiencies were 26 ± 2.4% (n = 6) for Effectene, 14 ± 2.9% for Fugene 6, and 15 ± 3.2% (n = 5) for DOTAP at 24°C. At 6°C, percent transfection was 6 ± 0.5% (n = 2) for Effectene, 8 ± 1.5% (n = 2) for Fugene 6, and 6 ± 0.0% (n = 2) for DOTAP.
also showed that efficiency of transfection using lipid has been previously documented using the commercial lipid-based reagents assessed in this study. Furthermore, reagents is largely temperature dependent (Fig. 5 ).
We presume that the observed transfection results we conclude that efficiency of lipofection is adversely affected by the decreasing temperatures, and among the from this study could be extended to relevant ECs of other origins (i.e., aortic, microvascular) given the ap-three lipid reagents Effectene appears to perform relatively better at the experimental temperatures evaluated propriate lipid reagent and sufficient optimization of the transfection protocol. Nonetheless, actual transfection in this study.
In future studies we are proposing to use lipofection experiments would have to be performed in other EC types to be certain about the level of efficiency. We to deliver the telomerase gene into endothelial cells. Our aim is to assess for the expression of telomerase in pri-chose HUVECs rather than other EC types due to the ease of attaining these ECs and they could be propagated mary ECs and whether these telomerase-transfected ECs have delayed replicative senescence and to what degree. to a sufficient mass in reasonable time for experimental studies. Other studies (22, 33) have demonstrated trans-Ultimately, we want to move onto translational studies in an allogeneic mouse model to assess the effects of fection in other EC types, including brain microvessel ECs and pulmonary aortic ECs. Kovala et al. achieved telomerase-transfected ECs on the longevity of allografts prior to human trials. efficiencies of approximately 50% as reported by GFP expression in aortic ECs using Fugene 6 with adequate
